Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial

CONCLUSIONS: Toripalimab plus bevacizumab showed a favorable efficacy and safety profile, supporting further studies of this combination regimen as a first-line treatment of advanced HCC.PMID:38687583 | DOI:10.1158/1078-0432.CCR-24-0006

Source: Clinical Cancer Research - April 30, 2024 Category: Cancer & Oncology Authors: Yajin Chen Cheng-You Du Shunli Shen Wu Zhang Yunfeng Shan Ang Lyu Jianhui Wu Changzhen Shang Xuan Luo Jinxing Wei Heng Xiao Jianguo Qiu Yunpeng Hua Shutong Wang Ting Wang Shengjie Dai Shuhao Zhang Bingying Xie Yinghao Wu Chunyi Hao Source Type: research